Three familiar US Food and Drug Administration pathways are available to sponsors who wish to use convalescent plasma to treat coronavirus, although one has been modified for streamlined use.
Convalescent plasma involves use of hyperimmune globulins manufactured from concentrated pathogen-specific antibodies in plasma donated by patients that have recovered from a coronavirus infection
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?